Evidence map›Paper›PMID 33643929›Full record

ReviewFrontiers in cellular and infection microbiology2020

Viral Infections, the Microbiome, and Probiotics.

Ashton Harper, Vineetha Vijayakumar, Arthur C Ouwehand, Jessica Ter Haar, David Obis, Jordi Espadaler, Sylvie Binda, Shrilakshmi Desiraju, Richard Day

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05157425 (Efficacy and Safety of a Multistrain Probiotic Formula to Boost the Immune Response to Influenza Virus Vaccination), which is not on this map. Cited by 93 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 3 pooled it
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05157425 nacompletednot on this mapstarted 2021, after this paper: background citation

Efficacy and Safety of a Multistrain Probiotic Formula to Boost the Immune Response to Influenza Virus Vaccination

TypeinterventionalSponsorAB Biotics, SARan2021 to 2022Enrolled140ConditionsInfluenza VaccineArmsFood Supplement, Placebo
3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 3 syntheses or guidelines pooled it, 175 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 4 countries.

Ashton HarperADM Health & Wellness, Medical Affairs Department, Somerset, United Kingdom.
Vineetha VijayakumarADM Health & Wellness, Medical Affairs Department, Somerset, United Kingdom.
Arthur C OuwehandGlobal Health and Nutrition Sciences, DuPont Nutrition and Biosciences, Kantvik, Finland.
Jessica Ter HaarScientific Committee, IPA, Los Angeles, CA, United States.
David ObisInnovation Science & Nutrition Department, Danone Nutricia Research, Palaiseau, France.
Jordi EspadalerInnovation, AB-BIOTICS S.A., Barcelona, Spain.
Sylvie BindaLallemand Health Solutions, Montreal, QC, Canada.
Shrilakshmi DesirajuTriphase Pharmaceuticals, Pvt Ltd, Karnataka, India.
Richard DayADM Health & Wellness, Medical Affairs Department, Somerset, United Kingdom.
AB-Biotics (Spain) · ESDanone (France) · FRDuPont (Finland) · FILallemand (Canada) · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Viral infections continue to cause considerable morbidity and mortality around the world. Recent rises in these infections are likely due to complex and multifactorial external drivers, including climate change, the increased mobility of people and goods and rapid demographic change to name but a few. In parallel with these external factors, we are gaining a better understanding of the internal factors associated with viral immunity. Increasingly the gastrointestinal (GI) microbiome has been shown to be a significant player in the host immune system, acting as a key regulator of immunity and host defense mechanisms. An increasing body of evidence indicates that disruption of the homeostasis between the GI microbiome and the host immune system can adversely impact viral immunity. This review aims to shed light on our understanding of how host-microbiota interactions shape the immune system, including early life factors, antibiotic exposure, immunosenescence, diet and inflammatory diseases. We also discuss the evidence base for how host commensal organisms and microbiome therapeutics can impact the prevention and/or treatment of viral infections, such as viral gastroenteritis, viral hepatitis, human immunodeficiency virus (HIV), human papilloma virus (HPV), viral upper respiratory tract infections (URTI), influenza and SARS CoV-2. The interplay between the gastrointestinal microbiome, invasive viruses and host physiology is complex and yet to be fully characterized, but increasingly the evidence shows that the microbiome can have an impact on viral disease outcomes. While the current evidence base is informative, further well designed human clinical trials will be needed to fully understand the array of immunological mechanisms underlying this intricate relationship.

Indexed as

AnimalsCOVID-19DysbiosisGastrointestinal MicrobiomeHost Microbial InteractionsHumansMicrobiotaProbioticsSARS-CoV-2Viral VaccinesVirus DiseasesViral Vaccinesdysbiosisimmunitymicrobiomeprobioticsviral infection

Identifiers

PMID33643929
PMCPMC7907522
OpenAlexW3132617495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.